144 related articles for article (PubMed ID: 22452920)
21. MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models.
Duffield JS; Grafals M; Portilla D
Drug Discov Today Dis Models; 2013; 10(3):e127-e135. PubMed ID: 25018773
[TBL] [Abstract][Full Text] [Related]
22. Riddling Substitution of "hsa" to "has" in the Enigmatic MicroRNA Nomenclature.
Vishwakarma R; Ramakrishnan K; Rehman N
OMICS; 2024 Apr; 28(4):165-169. PubMed ID: 38588572
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian Graphical Model for Integrative Analysis of TCGA Data.
Xu Y; Zhang J; Yuan Y; Mitra R; Müller P; Ji Y
IEEE Int Workshop Genomic Signal Process Stat; 2012 Dec; 2012():135-138. PubMed ID: 25859418
[TBL] [Abstract][Full Text] [Related]
24. A miRNA signature assessing ovarian cancer prognosis.
Bagnoli M; Pignata S; Mezzanzanica D
Oncoscience; 2016; 3(11-12):308-310. PubMed ID: 28105451
[No Abstract] [Full Text] [Related]
25. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
26. RAD51AP1 promotes progression of ovarian cancer via TGF-β/Smad signalling pathway.
Zhao H; Gao Y; Chen Q; Li J; Ren M; Zhao X; Yue W
J Cell Mol Med; 2021 Feb; 25(4):1927-1938. PubMed ID: 33314567
[TBL] [Abstract][Full Text] [Related]
27. [Research Advances of RAD51AP1 in Tumor Progression and Drug Resistance].
Liu R; Li M; Hu Z; Song Z; Chen J
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):701-708. PubMed ID: 37985156
[TBL] [Abstract][Full Text] [Related]
28. Cellular signaling modulated by miRNA-3652 in ovarian cancer: unveiling mechanistic pathways for future therapeutic strategies.
Imran K; Iqbal MJ; Abid R; Ahmad MM; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2023 Oct; 21(1):289. PubMed ID: 37845675
[TBL] [Abstract][Full Text] [Related]
29. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.
Schwarzenbach H; Gahan PB
Cancer Drug Resist; 2019; 2(2):271-296. PubMed ID: 35582723
[TBL] [Abstract][Full Text] [Related]
30. MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers.
Sharma PC; Gupta A
Transl Cancer Res; 2020 Sep; 9(9):5798-5818. PubMed ID: 35117940
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive bioinformatics analysis to identify a candidate prognostic biomarker for ovarian cancer.
Zhu H; Yue H; Xie Y; Du Q; Chen B; Zhou Y; Liu W
Transl Cancer Res; 2021 Mar; 10(3):1537-1548. PubMed ID: 35116478
[TBL] [Abstract][Full Text] [Related]
32. LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression.
Qiao ZW; Jiang Y; Wang L; Wang L; Jiang J; Zhang JR; Mu P
BMC Cancer; 2021 Sep; 21(1):1004. PubMed ID: 34496800
[TBL] [Abstract][Full Text] [Related]
33. Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
Lopacinska-Jørgensen J; Oliveira DVNP; Wayne Novotny G; Høgdall CK; Høgdall EV
PLoS One; 2021; 16(7):e0255142. PubMed ID: 34320033
[TBL] [Abstract][Full Text] [Related]
34. Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells.
Mitra A; Yoshida-Court K; Solley TN; Mikkelson M; Yeung CLA; Nick A; Lu K; Klopp AH
Sci Rep; 2021 Apr; 11(1):9149. PubMed ID: 33911091
[TBL] [Abstract][Full Text] [Related]
35. Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer.
Liu J; Yoo J; Ho JY; Jung Y; Lee S; Hur SY; Choi YJ
J Ovarian Res; 2021 Apr; 14(1):59. PubMed ID: 33910598
[TBL] [Abstract][Full Text] [Related]
36. Circ_0008039 supports breast cancer cell proliferation, migration, invasion, and glycolysis by regulating the miR-140-3p/SKA2 axis.
Dou D; Ren X; Han M; Xu X; Ge X; Gu Y; Wang X; Zhao S
Mol Oncol; 2021 Feb; 15(2):697-709. PubMed ID: 33244865
[TBL] [Abstract][Full Text] [Related]
37. Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer.
Levy-Jurgenson A; Tekpli X; Kristensen VN; Yakhini Z
Sci Rep; 2020 Nov; 10(1):18802. PubMed ID: 33139755
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma.
Sato C; Osakabe M; Nagasawa T; Suzuki H; Itamochi H; Baba T; Sugai T
Oncol Lett; 2020 Dec; 20(6):338. PubMed ID: 33123249
[TBL] [Abstract][Full Text] [Related]
39. The miR-34 family and its clinical significance in ovarian cancer.
Welponer H; Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Marth C; Hackl H; Fiegl H; Zeimet AG
J Cancer; 2020; 11(6):1446-1456. PubMed ID: 32047551
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-590-5p promotes cell survival in endometrioid endometrial cancer by suppressing tumor suppressor PTEN.
Zhu M; Zhou X; Zhang J; Zhang Y
Int J Clin Exp Pathol; 2017; 10(7):7836-7846. PubMed ID: 31966631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
